Glaukos
Breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | $53.2m | Post IPO Convertible |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 31 % | (4 %) | 11 % | 22 % | 26 % | 26 % | 24 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (22 %) | (37 %) | (26 %) | (21 %) | (8 %) | 6 % | 14 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (17 %) | (35 %) | (43 %) | (38 %) | (15 %) | (1 %) | 7 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 38 % | 44 % | 46 % | 36 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Glaukos Corporation is a medical technology company focused on developing and commercializing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company primarily serves ophthalmologists and their patients, operating within the global ophthalmic market. Glaukos pioneered micro invasive glaucoma surgery (MIGS) and launched the first US-approved MIGS device, the Trabecular Micro Bypass Stent, in 2012. The company continues to innovate with its next-generation iStent device, introduced in 2018. Glaukos generates revenue through the sale of its medical devices and therapies to healthcare providers and institutions. The company's business model is centered on continuous research and development, strategic acquisitions, and expanding its product portfolio to address unmet medical needs in ophthalmology.
Keywords: glaucoma, corneal disorders, retinal diseases, micro invasive surgery, MIGS, iStent, ophthalmology, medical devices, innovation, patient care.
Tech stack
Investments by Glaukos
Edit